Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(75%)
Terminated
1(25%)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_1
3
75%

Phase Distribution

3

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Terminated(1)

Detailed Status

Recruiting3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 13 (75.0%)
N/A1 (25.0%)

Trials by Status

recruiting375%
terminated125%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_1

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT05098210
recruitingphase_1

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

NCT05269381
recruitingnot_applicable

Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors

NCT05749627
terminatedphase_1

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

NCT03956056

Clinical Trials (4)

Showing 4 of 4 trials
NCT05098210Phase 1

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Recruiting
NCT05269381Phase 1

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Recruiting
NCT05749627Not Applicable

Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors

Recruiting
NCT03956056Phase 1

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Terminated

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4